ImmuPharma plc (LON:IMM – Get Free Report) traded up 191.7% on Thursday . The stock traded as high as GBX 3.78 ($0.05) and last traded at GBX 3.50 ($0.04). 96,678,711 shares changed hands during trading, an increase of 468% from the average session volume of 17,022,506 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Up 4.9 %
The company has a market capitalization of £15.30 million, a P/E ratio of -367.30 and a beta of 1.53. The company has a 50-day moving average of GBX 1.40 and a two-hundred day moving average of GBX 1.65.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- Investing in the High PE Growth Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Buy Cheap Stocks Step by Step
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
